Iterum Therapeutics plc (ITRM)
After hours:
| Previous Close | 0.9400 |
| Open | 0.9400 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.8900 - 1.0300 |
| 52 Week Range | 0.6010 - 7.0200 |
| Volume | |
| Avg. Volume | 88,275 |
| Market Cap | 12.091M |
| Beta (5Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4500 |
| Earnings Date | Mar 16, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
- Thomson Reuters StreetEvents
Q4 2022 Iterum Therapeutics PLC Earnings Call
Q4 2022 Iterum Therapeutics PLC Earnings Call
- GlobeNewswire
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter
- GlobeNewswire
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and fully year 2022 financial results before the open of the U.S. financial markets on Thursday, March 16, 2023.
